Robust Immune Responses for Herpes Zoster Subunit Vaccine

Share this content:
Robust Immune Responses for Herpes Zoster Subunit Vaccine
Robust Immune Responses for Herpes Zoster Subunit Vaccine

MONDAY, May 21, 2018 (HealthDay News) -- Recipients of the herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01B Adjuvant System, develop robust immune responses, according to a study published in the June 1 issue of The Journal of Infectious Diseases.

Anthony L. Cunningham, M.D., from the University of Sydney, and colleagues presented immunogenicity results from two trials involving patients aged 50 years or older and aged 70 years or older who received two doses of HZ/su or placebo two months apart. In subcohorts with 3,293 and 466 participants for humoral and cell-mediated immunogenicity, respectively, serum anti-gE antibodies and CD4 T-cells expressing two or more of four activation markers assessed after stimulation with gE-peptides were measured.

The researchers identified a humoral response in 97.8 and 2 percent of HZ/su and placebo recipients, respectively, after vaccination. At one and 36 months post-dose 2, geometric mean anti-gE antibody concentrations increased 39.1- and 8.3-fold, respectively, over baseline in HZ/su recipients. In 93.3 and 0 percent of HZ/su and placebo recipients, respectively, there was a gE-specific CD42+ T-cell response. In HZ/su recipients, median CD42+ T-cell frequencies increased 24.6- and 7.9-fold over baseline at one and 36 months, respectively; in all age groups, the frequency remained ≥5.6-fold above baseline at 36 months. In all age groups there was an increase in the proportion of CD4 T-cells expressing all four activation markers over time.

"Most HZ/su recipients developed robust immune responses persisting for three years following vaccination," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including GlaxoSmithKline Biologicals SA, which funded the study.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Global Prevalence of Insufficient Activity 27.5 Percent

Global Prevalence of Insufficient Activity 27.5 Percent

Levels of insufficient physical activity stable between 2001, 2016; increase seen in high-income countries

HTN Tx Intensification Common Upon Discharge in U.S. Vets

HTN Tx Intensification Common Upon Discharge in U.S. ...

Fourteen percent of older adults admitted to hospital for non-cardiac conditions had intensification of tx

Quarterly Canakinumab Reduces Risk for Gout Attacks

Quarterly Canakinumab Reduces Risk for Gout Attacks

Doesn't affect serum uric acid levels over time, but targets interleukin-1β

is free, fast, and customized just for you!




Already a member?

Sign In Now »